The Cardiovascular Advisory Committee review positions Inari Medical's latest device as substantially equivalent, potentially expanding treatment options in a competitive market.
Inari Medical, Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Triever Duo Catheter. The device, designated with product code QEW, was cleared on September 18, 2026, marking it as substantially equivalent to existing devices on the market.
This Traditional 510(k) clearance places the Triever Duo Catheter in Class 2 under regulation number 870.5150, which pertains to cardiopulmonary bypass accessories. The review was conducted by the Cardiovascular Advisory Committee.
Device Overview
The Triever Duo Catheter is an accessory used in cardiopulmonary bypass procedures. While specific design details beyond its classification as a catheter and its intended use are not disclosed in the clearance summary, the 'Duo' designation suggests potential for dual functionality or lumen design, common in such devices to facilitate simultaneous aspiration, infusion, or monitoring.
Cardiopulmonary bypass accessories are critical components in procedures requiring temporary support of heart and lung function, such as complex cardiac surgeries or interventions. The 'Triever' product line from Inari Medical typically focuses on clot removal, and while not explicitly stated for this specific clearance, the branding suggests a potential role in facilitating such procedures.
Market Implications and Regulatory Context
The clearance as "substantially equivalent" indicates that the FDA found the Triever Duo Catheter to be as safe and effective as a legally marketed predicate device. This pathway bypasses the need for new clinical trials to demonstrate safety and efficacy, often expediting market access for device manufacturers.
The cardiovascular device market is characterized by ongoing innovation and a focus on minimizing invasiveness and improving patient outcomes. The introduction of new tools that streamline procedures or enhance physician capabilities can be a differentiating factor. Specific market availability, pricing, or the device's exact clinical indications beyond its broad product code classification have not yet been disclosed by Inari Medical.
The clearance enables Inari Medical to expand its portfolio in the cardiovascular space, a sector with consistent demand for advanced interventional tools.
